Jeremy Lorber, MD: I have 1 other point to touch on. Neil Minkoff, MD: Please. Jeremy Lorber, MD: Dr [Jeremy] Gleeson said that [cold agglutin disease] is a rare disease in which pathways aren’t ...

In people with CAD, cold agglutinins tend to be activated when their temperature drops to between 28 and 31 degrees C (82.4 and 87.8 degrees F), but they can be activated at higher temperatures ...

Cold agglutinin disease (CAD), a rare hemolytic anemia, ... 1-11) therapies and a mean 2.94 (standard deviation, 8.45) blood transfusions within the first 6 months.

Cold agglutinin disease is a rare autoimmune ... J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood ...

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...

Cold autoimmune hemolytic anemia (c-AIHA), or cold agglutinin disease (CAD), most commonly affects adults between 40 and 80 years old. With CAD, antibodies activate at cooler temperatures and ...

A review published in the journal Immunotherapy summarizes the applications of sutimlimab and emphasizes the importance of individualizing treatment for patients with cold agglutinin disease.

Dr. Roach: What are the symptoms for cold agglutinin disease, and how is it diagnosed? — P.W. Answer: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a ...

red blood cells The FDA has granted Priority Review for the Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease, a rare ...

Given that cold agglutinin disease is a chronic condition, the annual cost of the therapy comes to $280,800. It’s more for those who weigh greater than 75 kg because these patients will require ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures.

FDA approves expanded label of Enjaymo ® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease. News release. January 25, 2023.